TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22445441
Drug: Doubling of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling of statin dose
Study: 20491720
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy for psychosis (CBTp)
Study: 18949295
Drug: Ca(OH)2 +
Normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)2 + 2% chlorhexidine gluconate (CHX) gel
Study: 12182236
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg orally)
Study: 8776184
Drug: Autotransfusion without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Autotransfusion without heparin-bonded circuit (Group 2)
Study: 8776184
Drug: Autotransfusion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autotransfusion with heparin-bonded circuit (Group 3)
Study: 1632172
Drug: Vf of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vf of 50 ml.kg‐1.min‐1 (Group 1)
Study: 1632172
Drug: Vf of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vf of 75 ml.kg‐1.min‐1 (Group 2)
Study: 1632172
Drug: Vf of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vf of 100 ml.kg‐1.min‐1 (Group 3)
Study: 1632172
Drug: Vf of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vf of 100 ml.kg‐1.min‐1 for 15 min, 75 ml.kg‐1.min‐1 for the next 15 min and 50 ml.kg‐1.min‐1 thereafter (Group 4)
Study: 1632172
Drug: Vf of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vf of 25 ml.kg‐1.min‐1 for 10 min and switched off for the remainder of the procedure (Group 5)
Study: 29684771
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation at a daily dose of 30 mg for 100 days
Study: 29684771
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation at a daily dose of 60 mg for 100 days
Study: 24290594
Drug: Yeast hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast hydrolysate 1 g/d
Study: 24290594
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 g/d
Study: 20850091
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of abciximab through the guiding catheter
Study: 20850091
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of abciximab
Study: 12577328
Drug: Combined HACE
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined HACE and Chinese herbal medicine (Gan'ai No. I and No. II)
Study: 3034690
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of LTB4
Study: 3034690
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 12-HETE
Study: 3034690
Drug: Control lesions
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control lesions (not specified treatment)
Study: 2543582
Drug: Natural or
Normalized name: Dex4 Natural Orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural or synthetic retinoids (RA, acitretin, isotretinoin, Ro137410, retinol) applied daily for 4 days
Study: 2543582
Drug: Topical dithranol
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dithranol treatment, UVB irradiation, or scotch tape stripping
Study: 2543582
Drug: Topical diflucortolone
Normalized name: diflucortolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diflucortolone
Study: 17880315
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous catheter
Study: 21348213
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of ephedrine intravenously (EPHE‐5)
Study: 21348213
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of ephedrine intravenously (EPHE‐10)
Study: 21348213
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of HES 130/0.4 in rapid infusion over 15 minutes
Study: 19130635
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture treatment group
Study: 11515884
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g bolus before skin incision, followed by continuous infusion of 400 mg/hr during surgery)
Study: 8498877
Drug: New psychopharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New psychopharmacologic treatments
Study: 23590271
Drug: Dead space
Normalized name: UltiCare 3mL 22G 1-1/2 inch Low Dead Space Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dead space (DS) loading of 0.6 L during exercise
Study: 23590271
Drug: Dead space
Normalized name: UltiCare 3mL 22G 1-1/2 inch Low Dead Space Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dead space (DS) loading of 0.6 L at 60 W
Study: 19221371
Drug: Drug facts
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug facts box in symptom drug box trial
Study: 19221371
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (actual drug ads) in symptom drug box trial
Study: 19221371
Drug: Drug facts
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug facts box in prevention drug box trial
Study: 19221371
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (actual drug ads) in prevention drug box trial
Study: 22142537
Drug: SunshowerMedical home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SunshowerMedical home UV device, used daily for 6 minutes over 6 weeks
Study: 22142537
Drug: Hospital UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital UVB treatment (Waldmann 85/UV21 lamps), twice a week for 6 weeks
Study: 21456039
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg/day plus modafinil 400 mg/day (200 mg bid)
Study: 19496103
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg/day plus placebo
Study: 16522393
Drug: Antibiotics (metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (metronidazole 250 mg and erythromycin 250 mg tid orally for 7 days prenatally, metronidazole 250 mg and ampicillin 500 mg q 4 hours during labor)
Study: 16522393
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and Placebo
Study: 8982890
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with 1.5 ml/kg of 0.2% bupivacaine (Group I)
Study: 8982890
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration of the surgical site with up to 1.2 ml/kg of 0.25% bupivacaine (Group 2)
Study: 6099055
Drug: Etomidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.3 mg/kg body wt.)
Study: 6099055
Drug: Thiopentone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4 mg/kg body wt.)
Study: 19104775
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 60 mg
Study: 2044903
Drug: Oral omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral omeprazole (80 mg)
Study: 6266642
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with MER (methanol-extracted residue of bacillus Calmette-Guerin)
Study: 6266642
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy without MER
Study: 22940119
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone once daily from the day after insemination until 12 weeks of pregnancy or for 14 days in non-pregnant women
Study: 20590478
Drug: SJW 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJW 300 mg
Study: 20590478
Drug: SJW 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJW 600 mg
Study: 17566826
Drug: Rectal contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal contrast CT
Study: 12394765
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose intravesical BCG (120 mg)
Study: 12394765
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose intravesical BCG (40 mg)
Study: 12394765
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of intravesical BCG
Study: 9783492
Drug: Perindopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (ACE inhibitor) alone or in combination with indapamide (diuretic)
Study: 8197045
Drug: Erythromycin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 1.0 g/day for 10 days
Study: 2853457
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (16 mg daily)
Study: 25919011
Drug: Pain Exposure
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Exposure Physical Therapy
Study: 12507208
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy plus radiation therapy
Study: 10457792
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg once daily for 2 weeks, then increased to 10 mg once daily if diastolic blood pressure did not fall below 90 mmHg
Study: 30284065
Drug: Egg ovalbumin-derived
Normalized name: ovalbumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg ovalbumin-derived protein hydrolysate (3 g/day)
Study: 30284065
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 g/day)
Study: 28646591
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cryotherapy and salicylic acid
Study: 27871759
Drug: Basiliximab induction
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab induction with low-dose tacrolimus, mycophenolate mofetil, and steroid maintenance therapy (arm A)
Study: 24383930
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist (IL-1Ra) 500 mg bolus, then 10 mg/kg/hr infusion for 24 hours
Study: 22854400
Drug: High-energy density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy density preload (0.97 kcal/g)
Study: 22854400
Drug: Low-energy density
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy density preload (0.57 kcal/g)
Study: 17097152
Drug: Xylitol 7.5g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol 7.5g once daily (QD)
Study: 16109574
Drug: Esomeprazole-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole-based therapy (20 mg esomeprazole, 1000 mg amoxicillin, 500 mg clarithromycin twice daily for 7 days)
Study: 16109574
Drug: Omeprazole-based therapy
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole-based therapy (20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin twice daily for 7 days)
Study: 16109574
Drug: Esomeprazole-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole-based therapy
Study: 16109574
Drug: Omeprazole-based therapy
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole-based therapy
Study: 9469333
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 800 IU daily
Study: 23756608
Drug: Open-label LDX
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label LDX (20-70 mg/day)
Study: 19840500
Drug: Immediate post
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate post space preparation using LA Axxess burs
Study: 19840500
Drug: Delayed post
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed post space preparation using LA Axxess burs
Study: 19840500
Drug: Immediate post
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate post space preparation using heated pluggers
Study: 19840500
Drug: Delayed post
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed post space preparation using heated pluggers
Study: 19840500
Drug: Immediate post
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate post space preparation using solvent delivered with a hand file
Study: 19840500
Drug: Delayed post
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed post space preparation using solvent delivered with a hand file
Study: 9305328
Drug: Intravenous levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous levodopa (LD) administered over a wide dose range
Study: 9305328
Drug: Higher levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Higher levodopa doses
Study: 9305328
Drug: Smaller, more
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smaller, more frequent levodopa doses
Study: 9596230
Drug: Nonusers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonusers of aspirin
Study: 22694484
Drug: Sumatriptan iontophoretic
Normalized name: Sumatriptan Iontophoretic Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan iontophoretic transdermal system
Study: 12720115
Drug: EMD plus
Normalized name: EMD-1201081
DrugBank: EMD-1201081 (DB06181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMD plus selective COX-2 inhibitor (rofecoxib 12.5 mg twice daily for 14 days)
Study: 1514343
Drug: Lignocaine 10
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 10 mg mixed with propofol
Study: 27298402
Drug: Salvage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage treatment for HT
Study: 19127436
Drug: Indinavir-loaded microparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir-loaded microparticles (15% drug load)
Study: 19127436
Drug: Indinavir-loaded microparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir-loaded microparticles (90% drug load)
Study: 17609916
Drug: Glossy Ganoderma
Normalized name: Ganoderma lucidum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glossy Ganoderma Decoction (GGD) combined with conventional treatment (penicillin and reduced glutathione)
Study: 17609916
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (penicillin and reduced glutathione) alone
Study: 11829202
Drug: Fluconazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (150 mg weekly)
Study: 9625398
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder (900 mg/d)
Study: 7836218
Drug: Buffer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffer treatment (alkali loading) during constant-intensity exercise at 85% of maximal exertion
Study: 24028076
Drug: No LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No LH rise prior to ganirelix treatment
Study: 24028076
Drug: No LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No LH rise during ganirelix treatment
Study: 24028076
Drug: Women with
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with LH rise during ganirelix treatment
Study: 21255534
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg and ASA 325 mg in a single capsule
Study: 21255534
Drug: Separate monotherapies
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate monotherapies of esomeprazole 40 mg and ASA 325 mg
Study: 2651244
Drug: Beta-interferon gel
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-interferon gel (100,000 IU/g), self-administered 4 times daily to the affected areas.
Study: 31825248
Drug: NovoLog® (US-sourced
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovoLog® (US-sourced insulin aspart)
Study: 31825248
Drug: NovoRapid® (EU-sourced
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovoRapid® (EU-sourced insulin aspart)
Study: 25539467
Drug: Corticosteroid continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid continuation (CC)
Study: 21775111
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (Losartan)
Study: 19635145
Drug: Powdered supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered supplement (30 mg iron as micronized dispersible ferric pyrophosphate, 600 mug folic acid)
Study: 19635145
Drug: Tablet supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet supplement (27 mg iron from ferrous fumarate, 1000 mug folic acid)
Study: 15243305
Drug: L-NMMA (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (0.8 mg/min/dL)
Study: 15243305
Drug: L-NMMA (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (1.6 mg/min/dL)
Study: 15243305
Drug: L-NMMA (EC50)
Normalized name: L
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (EC50)
Study: 15243305
Drug: L-NMMA (Maximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (Maximal vasoconstrictive response)
Study: 9271777
Drug: GHRH (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (50 micrograms hourly between 22.00 h and 1.00 h, 4 x 50 micrograms)
Study: 8188163
Drug: Interferon-alpha 2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha 2a high dose (18 MU/day)
Study: 8188163
Drug: Interferon-alpha 2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha 2a low dose (3 MU/day)
Study: 2897008
Drug: Ceftriaxone 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 4 g/day
Study: 29520533
Drug: Acupuncture (AC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (AC) - twice weekly manual acupuncture over six weeks
Study: 27943570
Drug: Telephone-Delivered Cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-Delivered Cognitive Behavioural Therapy (T-CBT)
Study: 27943570
Drug: CBT face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT face to face treatment as usual (TAU-CBT)
Study: 21672205
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) - 5 to 10 sessions based on the Salkovskis/Warwick model.
Study: 18490527
Drug: Abciximab (glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abciximab (glycoprotein IIb/IIIa inhibitor)
Study: 18490527
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Stenting with both embolic protection and abciximab)
Study: 12973486
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lamivudine daily for 6 months
Study: 1330079
Drug: Immune Globulin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune Globulin Intravenous
Study: 29252011
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy (MET) plus Family Check-Up (FCU)
Study: 26695436
Drug: NB‐UVB therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB‐UVB therapy plus intradermal injection of PRP every 2 weeks for 4 months
Study: 15946597
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Cloril tablet (Test formulation)
Study: 15946597
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Clozaril tablet (Reference formulation)
Study: 11942772
Drug: Gemfibrozil (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (900 mg)
Study: 14572169
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate (200 mg)
Study: 11316966
Drug: Azelastine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (4 mg)
Study: 10322842
Drug: Baoyuan Qiangshen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baoyuan Qiangshen (BQ) II tablet
Study: 3098129
Drug: 4% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% sodium cromoglycate (SCG) in an oil-in-water cream
Study: 3098129
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo cream
Study: 29098469
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control diet with total fish oil replacement and defatted fish meal containing 0.1-g ARA g‐1 diet